HC Wainwright Reiterates “Neutral” Rating for Inhibikase Therapeutics (NYSE:IKT)

HC Wainwright reaffirmed their neutral rating on shares of Inhibikase Therapeutics (NYSE:IKT) in a research note released on Friday,Benzinga reports.

Inhibikase Therapeutics Stock Down 3.4 %

Shares of NYSE IKT opened at $2.29 on Friday. The stock has a market capitalization of $158.84 million, a PE ratio of -0.86 and a beta of 1.04. The firm has a fifty day moving average of $2.42 and a 200-day moving average of $2.38. Inhibikase Therapeutics has a 52-week low of $1.12 and a 52-week high of $4.20.

Hedge Funds Weigh In On Inhibikase Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Blair William & Co. IL increased its position in Inhibikase Therapeutics by 7.0% during the 4th quarter. Blair William & Co. IL now owns 134,953 shares of the company’s stock worth $439,000 after purchasing an additional 8,833 shares in the last quarter. Stifel Financial Corp purchased a new stake in Inhibikase Therapeutics during the fourth quarter worth approximately $43,000. Jefferies Financial Group Inc. acquired a new stake in shares of Inhibikase Therapeutics in the fourth quarter worth $48,000. Alpine Global Management LLC purchased a new position in shares of Inhibikase Therapeutics in the 4th quarter valued at $48,000. Finally, Caxton Corp acquired a new position in shares of Inhibikase Therapeutics during the 4th quarter valued at $53,000. 3.81% of the stock is owned by institutional investors and hedge funds.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.